Impacts of peroxisome proliferatoractivated receptor-γ activation on cigarette smoke-induced exacerbated response to bacteria

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 191-200

  Morissette, Mathieu C ^a   Shen, Pamela ^b   Thayaparan, Danya ^b   Stämpfli, Martin R ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; DEXAMETHASONE SODIUM PHOSPHATE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CORTICOSTEROID; DEXAMETHASONE;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HAEMOPHILUS INFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; INFECTION CONTROL; LUNG ALVEOLUS MACROPHAGE; MOUSE; NEUTROPHILIA; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PHAGOCYTOSIS; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; ADVERSE EFFECTS; ANIMAL; BACTERIAL INFECTION; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; LUNG; MACROPHAGE; METABOLISM; MICROBIOLOGY; NEUTROPHIL; PATHOPHYSIOLOGY; SMOKING; TOBACCO;

ADRENAL CORTEX HORMONES; ANIMALS; BACTERIAL INFECTIONS; BRONCHOALVEOLAR LAVAGE FLUID; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; LUNG; MACROPHAGES; MICE; MICE, INBRED C57BL; NEUTROPHILS; PNEUMONIA; PPAR GAMMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; THIAZOLIDINEDIONES; TOBACCO PRODUCTS;

EID: 84920591426     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00004314     Document Type: Article

References (33)

1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721.
2. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364.
3. Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7: 214-228.
4. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011; 37: 508-515.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
6. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013; 12: 543-559.
7. Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis 2008; 4: 12.
8. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150-157.
9. Sandhu SK, Chu J, Yurkovich M, et al. Variations in the management of acute exacerbations of chronic obstructive pulmonary disease. Can Respir J 2013; 20: 175-179.
10. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 2008; 77: 289-312.
11. Malur A, Mccoy AJ, Arce S, et al. Deletion of PPARγ in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol 2009; 182: 5816-5822.
12. Birrell MA, Patel HJ, McCluskie K, et al. PPAR-γ agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.
13. Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARγ agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther 2009; 22: 183-189.
14. Genovese T, Cuzzocrea S, Di Paola R, et al. Effect of rosiglitazone and 15-deoxy-δ12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25: 225-234.
15. Botelho FM, Gaschler GJ, Kianpour S, et al. Innate immune processes are sufficient for driving cigarette smoke-induced inflammation in mice. Am J Respir Cell Mol Biol 2010; 42: 394-403.
16. Bauer CM, Zavitz CC, Botelho FM, et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One 2010; 5: e13251.
17. Gaschler GJ, Skrtic M, Zavitz CC, et al. Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile. Am J Respir Crit Care Med 2009; 179: 666-675.
18. Gaschler GJ, Zavitz CC, Bauer CM, et al. Mechanisms of clearance of nontypeable Haemophilus influenzae from cigarette smoke-exposed mouse lungs. Eur Respir J 2010; 36: 1131-1142.
19. Botelho FM, Bauer CM, Finch D, et al. IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One 2011; 6: e28457.
20. Balamayooran G, Batra S, Cai S, et al. Role of CXCL5 in leukocyte recruitment to the lungs during secondhand smoke exposure. Am J Respir Cell Mol Biol 2012; 47: 104-111.
21. Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011; 3: 78ra32.
22. Thimmulappa RK, Gang X, Kim JH, et al. Oxidized phospholipids impair pulmonary antibacterial defenses: evidence in mice exposed to cigarette smoke. Biochem Biophys Res Commun 2012; 426: 253-259.
23. Clancy RL, Dunkley M. Acute exacerbations in COPD and their control with oral immunization with non-typeable Haemophilus influenzae. Front Immunol 2011; 2: 7.
24. O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD. Thorax 2006; 61: 448-454.
25. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28-S38.
26. Lea S, Plumb J, Metcalfe H, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J 2014; 43: 409-420.
27. Shan M, You R, Yuan X, et al. Agonistic induction of PPARγ reverses cigarette smoke-induced emphysema. J Clin Invest 2014; 124: 1371-1381.
28. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
29. Remels AH, Langen RC, Gosker HR, et al. PPARγ inhibits NF-κB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab 2009; 297: E174-E183.
30. Yamamoto K, Ahyi AN, Pepper-Cunningham ZA, et al. Roles of lung epithelium in neutrophil recruitment during pneumococcal pneumonia. Am J Respir Cell Mol Biol 2014; 50: 253-262.
31. Almeida PE, Carneiro AB, Silva AR, et al. PPARγ expression and function in Mycobacterial infection: roles in lipid metabolism, immunity, and bacterial killing. PPAR Res 2012; 2012: 383829.
32. Bortolini M, Wright MB, Bopst M, et al. Examining the safety of PPAR agonists -current trends and future prospects. Expert Opin Drug Saf 2013; 12: 65-79.
33. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.